● In July, Recombinant Human Albumin Injection (Oryza Sativa) approved by China NMPA（国药准字S20250039）.

● In Oct. Healthgen is listed on the Shanghai Stock Exchange(Stock code: 688765)

● Completed phase IIl clinical study of HY1001

● Granted the approval of phase I clinical trialsof HY1005-1 and HY1005-2

● Starting construction of the production line with an annual capacity of 12 million vials of OsrHSA

● The production line with an annual capacity of 1 million vials of OsrHSA was officially put into operation

● Started the global multicenter phase IIl of HY1001

● Granted the drug manufacturing license

● Moved to the new cGMP compliance plant with OsrHSA production capacity of 1 million vials

● HY1001 completed phase Il of clinical study in China

● HY1003 entered clinical trials phase I in US

● Starting Construction of Headquarter of Healthgen, Institute of Plant Molecular Pharming, a manufacturing plant with OsrHSA production capacity of 1 million vials

● Conducting a multicenter, phase Il of HY1002 in Patients with Decompensated Cirrhotic Ascites
● Conducting a multicenter, phase Il of HY1002 in Patients with diarrhoea caused by rotavirus in infants

● Submitting FDA IND application of HY1003

● Completed a phase I clinical study of HY1001(OsrHSA) in United States

● IND approval of HY1002 (recombinant humanlactoferrin and lysozyme oral solution) and promoted clinical phase I study in China

● Orphan drug consideration of HY1003(recombinant huam antitrypsin) was qualifiedby US FDA

● IND of OsrHSA was approved by by NMPA

● IND of OsrHSA was approved by by USFDA

● The state-of Art platform, Oryzᴴⁱᴱˣᵖ, honored the First Prize of Hubei Province Science and TechnologyInvention Award

● OsrHSA as pharmaceutical excipients was registered in FDA, Drug Master File (DMF) registered number (029648). Investigated Novel drug (IND) application of OsrHSA submitted to NMPA in China

● The state-of Art patent Method of high purity OsrHSA purification from rice grain, honored the First Prize of Hubei Province Science and Technology Invention Award. Established the state of Art recombinant protein purificationplatform, Oryzᵖᵘʳ

● Healthgen Biotech was founded. First successfully developed the State of Artrice endosperm expression platform, Oryzᴴⁱᴱˣᵖ in rice grain. Accomplished the lab-scale extraction andpurification process of OrsHSA

● Obtained the genetic engineered rice lines highly expressing recombinant human lactoferrin (OsrhLF) and recombinant human lysozyme (OsrhLYZ)
● Obtained the 5 millions RMB of Angel investment. The-State-of-Art expression platform Oryzᴴⁱᴱˣᵖ was identified by Hubei Province Science and Technology Achievement

● The pilot manufacturing facilities was run for OsrHSA production